Gastrointestinal symptoms in NSAID users in an 'average risk population': Results of a large population-based study in randomly selected Dutch inhabitants

International Journal of Clinical Practice

Volumn 68, Issue 4, 2014, Pages 512-519

  Tielemans, M M ^a,b   Van Rossum, L G M ^a   Eikendal, T ^a   Focks, J J ^a   Laheij, R J F ^c   Jansen, J B M J ^d   Van Oijen, M G H ^a,e,f  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^d ELKERLIEK HOSPITAL   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTON PUMP INHIBITOR; PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; DUTCH; EPIGASTRIC PAIN; ETHNIC GROUP; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HEARTBURN; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; POPULATION RESEARCH; POPULATION SIZE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESPONSE; VOMITING; CHEMICALLY INDUCED; DRUG INTERACTION; GASTROINTESTINAL DISEASES; MIDDLE AGED; QUESTIONNAIRE; RISK FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; NONPRESCRIPTION DRUGS; PRESCRIPTION DRUGS; PROTON PUMP INHIBITORS; RISK FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 84897091081     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12346     Document Type: Article

References (37)

1. Staff DT,. 2009 Top 200 generic drugs by total prescriptions. Drug Topics 2010; http://drugtopics.modernmedicine.com/ (accessed 10 February 2011).
2. Motola D, Vaccheri A, Silvani MC, et al. Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 2004; 60 (10): 731-8.
3. Lanas A, Hirschowitz BI,. Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999; 11 (4): 375-81.
4. Ofman JJ, Maclean CH, Straus WL, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003; 49 (4): 508-18.
5. Doyle G, Furey S, Berlin R, et al. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther 1999; 13 (7): 897-906.
6. Kellstein DE, Waksman JA, Furey SA, Binstok G, Cooper SA,. The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. J Clin Pharmacol 1999; 39 (5): 520-32.
7. Moore N, Le Parc JM, van Ganse E, Wall R, Schneid H, Cairns R,. Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain. Int J Clin Pract 2002; 56 (10): 732-4.
8. Thomas J, Straus WL, Bloom BS,. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms. Am J Gastroenterol 2002; 97 (9): 2215-9.
9. Wolfe MM, Lichtenstein DR, Singh G,. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340 (24): 1888-99.
10. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343 (8905): 1075-8.
11. Garcia Rodriguez LA, Jick H,. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343 (8900): 769-72.
12. Tielemans MM, Eikendal T, Jansen JB, van Oijen MG,. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010; 33 (6): 443-53.
13. van Kerkhoven LA, Eikendal T, Laheij RJ, van Oijen MG, Jansen JB,. Gastrointestinal symptoms are still common in a general Western population. Neth J Med 2008; 66 (1): 18-22.
14. Bovenschen HJ, Janssen MJ, van Oijen MG, Laheij RJ, van Rossum LG, Jansen JB,. Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci 2006; 51 (9): 1509-15.
15. van Marrewijk CJ, Mujakovic S, Fransen GA, et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Lancet 2009; 373 (9659): 215-25.
16. Likert R,. A technique for the measurement of attitudes. Archives of Psychology 1932; 140: 1-55.
17. White IR, Altmann DR, Nanchahal K,. Alcohol consumption and mortality: modelling risks for men and women at different ages. BMJ 2002; 325 (7357): 191.
18. WHO. Obesity: Preventing and Managing the Global Epidemic. Geneva: World Health Organisation, 2000.
19. DeArmond B, Francisco CA, Lin JS, et al. Safety profile of over-the-counter naproxen sodium. Clinical therapeutics 1995; 17 (4): 587-601; discussion 586.
20. Bjarnason I,. Gastrointestinal safety of NSAIDs and over-the-counter analgesics. Int J Clin Pract Suppl 2013; 67 (178): 37-42.
21. Valkhoff VE, van Soest EM, Sturkenboom MC, Kuipers EJ,. Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther 2010; 31 (11): 1218-28.
22. van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD,. Sociodemographic factors influence use of proton pump inhibitors among users of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol 2009; 7 (8): 855-61.
23. Thiefin G, Schwalm MS,. Underutilization of gastroprotective drugs in patients receiving non-steroidal anti-inflammatory drugs. Dig Liver Dis 2011; 43 (3): 209-14.
24. Helsper CW, Smeets HM, Numans ME, Knol MJ, Hoes AW, de Wit NJ,. Trends and determinants of adequate gastroprotection in patients chronically using NSAIDs. Pharmacoepidemiol Drug Saf 2009; 18 (9): 800-6.
25. Morini S, Zullo A, Oliveti D, et al. A very high rate of inappropriate use of gastroprotection for nonsteroidal anti-inflammatory drug therapy in primary care: a cross-sectional study. J Clin Gastroenterol 2011; 45 (9): 780-4.
26. Biskupiak JE, Brixner DI, Howard K, Oderda GM,. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother 2006; 20 (3): 7-14.
27. Singh G,. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000; 7 (2): 115-21.
28. Wilcox CM, Cryer B, Triadafilopoulos G,. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol 2005; 32 (11): 2218-24.
29. Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100 (5): 1028-36.
30. Hawkey CJ, Jones RH, Yeomans ND, et al. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2007; 25 (7): 813-21.
31. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101 (4): 701-10.
32. Tielemans MM, van Oijen MG, Mulder CJ, Vos KJ, Lems WF,. Esomeprazole relieves upper gastrointestinal symptoms in high-risk and average-risk NSAID users in daily clinical practice: results from an open-label study. Eur J Gastroenterol Hepatol 2012; 24 (3): 281-7.
33. French DP, James DH,. Reasons for the use of mild analgesics among English students. Pharm World Sci 2008; 30 (1): 79-85.
34. Ornbjerg LM, Andersen HB, Kryger P, Cleal B, Hetland ML,. What do patients in rheumatologic care know about the risks of NSAIDs? J Clin Rheumatol 2008; 14 (2): 69-73.
35. Sleath B, Rubin RH, Campbell W, Gwyther L, Clark T,. Physician-patient communication about over-the-counter medications. Soc Sci Med 2001; 53 (3): 357-69.
36. Numans ME, De Wit NJ, Dirven JAM, et al. [NHG Guideline on Dyspepsia (second revision)] NHG-Standaard Maagklachten (tweede herziening). Huisarts Wet 2013; 1 (56): 26-35.
37. Excellence NIfC. Clinical Guideline 17. Dyspepsia: management of dyspepsia of adults in primary care, 2004.